- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00113854
Mannitol as Adjunct Therapy for Childhood Cerebral Malaria
Effect of Mannitol as Adjunct Therapy on the Clinical Outcome of Childhood Cerebral Malaria in Mulago Hospital: A Randomised Clinical Trial
Study Overview
Detailed Description
Cerebral malaria is a life-threatening complication of Plasmodium falciparum infection accounting for significant morbidity and mortality in African children despite availability of quinine, the current drug of choice. The case fatality ranges from 5 to 40% with almost 10% of survivors experiencing neurological sequelae.
Several reports have suggested that raised intracranial pressure (ICP) may be a feature of cerebral malaria. There is evidence of brain swelling on computer tomography, magnetic resonance imaging and at necropsy. It has been postulated that raised intracranial pressure can cause death by transtentorial herniation or by compromising cerebral blood flow. In fact, most children who died of cerebral malaria in a Kenyan study, had clinical signs compatible with transtentorial herniation and all those who had severe ICP (maximum ICP > 40mmHg) either died or survived with neurological sequelae.
Mannitol, an osmotic diuretic, effectively lowers ICP and is used to treat post traumatic raised intracranial pressure. There have been some case reports of reduction in mortality and morbidity in African children with cerebral malaria following administration of mannitol, but as these were not randomized controlled trials it is difficult to evaluate their significance. Currently the WHO contends that there is insufficient evidence for using mannitol as adjunct therapy for cerebral malaria.
A recent Cochrane review found no randomized or quasi-randomized controlled trial to support or refute the use of mannitol as adjunct therapy for cerebral malaria.
Hypothesis: A single dose of intravenous mannitol (1g/kg) given to children with cerebral malaria will reduce mean coma recovery time from 22.5 to 13.1 hours.
We calculated a sample size of 78 patients in each group for 90% power and 95% confidence. In the calculation, we assumed that the children receiving intravenous mannitol would have a mean coma recovery time of 13.1 (SD 18.5) hours and those receiving placebo would have a mean coma recovery time of 22.5 (SD 18.5) hours (42.3% effect size), according to a recent study by Aceng, Byarugaba and Tumwine in the same hospital.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kampala, Uganda, P O Box 7072
- Department of Paediatrics and Child Health, Makerere Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Children aged 6 months to 5 years admitted to the Mulago hospital acute care unit during the study period with cerebral malaria: (seizures and unarousable coma lasting more than 30 minutes after seizures have stopped, with asexual forms of P. falciparum on the blood film, with no other cause of coma) and whose carers gave informed consent.
Exclusion Criteria:
- Children with evidence of having received any sedation within two hours prior to admission to the acute care unit.
- Also exclude children with clinical signs of pulmonary congestion, or heart failure, or renal disease, or shock
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Coma recovery time (that is time from beginning of antimalarial treatment until patient has fully regained consciousness).
|
Secondary Outcome Measures
Outcome Measure |
---|
Mortality
|
Time taken to sit un supported
|
Time to begin oral intake
|
Duration of hospitalisation
|
Proportion of children recovering with neurological sequelae
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Aceng JR, Byarugaba JS, Tumwine JK. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. BMJ. 2005 Feb 12;330(7487):334. doi: 10.1136/bmj.330.7487.334.
- Newton CR, Crawley J, Sowumni A, Waruiru C, Mwangi I, English M, Murphy S, Winstanley PA, Marsh K, Kirkham FJ. Intracranial hypertension in Africans with cerebral malaria. Arch Dis Child. 1997 Mar;76(3):219-26. doi: 10.1136/adc.76.3.219.
- Newton CR, Kirkham FJ, Winstanley PA, Pasvol G, Peshu N, Warrell DA, Marsh K. Intracranial pressure in African children with cerebral malaria. Lancet. 1991 Mar 9;337(8741):573-6. doi: 10.1016/0140-6736(91)91638-b.
- Okoromah CA, Afolabi BB. Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004615. doi: 10.1002/14651858.CD004615.pub2.
- Namutangula B, Ndeezi G, Byarugaba JS, Tumwine JK. Mannitol as adjunct therapy for childhood cerebral malaria in Uganda: a randomized clinical trial. Malar J. 2007 Oct 24;6:138. doi: 10.1186/1475-2875-6-138.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Central Nervous System Parasitic Infections
- Central Nervous System Protozoal Infections
- Malaria
- Malaria, Cerebral
- Physiological Effects of Drugs
- Natriuretic Agents
- Diuretics, Osmotic
- Diuretics
- Mannitol
Other Study ID Numbers
- HD200211/246
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Malaria
-
University of OxfordChittagong Medical College and HospitalCompleted
-
Claude Bernard UniversityUnknown
-
Makerere UniversityMinistry of Health, Uganda; Sanofi-SynthelaboUnknown
-
University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)CompletedEpilepsy | Seizure | Cerebral MalariaMalawi
-
University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)CompletedEpilepsy | Seizure | Cerebral MalariaMalawi
-
University of UtahNational Institute of Allergy and Infectious Diseases (NIAID); Duke University and other collaboratorsCompleted
-
U.S. Army Medical Research and Development CommandWalter Reed Army Institute of Research (WRAIR)Completed
-
Douglas Postels, MD, MSNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
U.S. Army Medical Research and Development CommandCompleted
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
Clinical Trials on Mannitol
-
Seoul National University HospitalUnknown
-
PharmaxisCompletedCystic FibrosisUnited Kingdom
-
Shandong UniversityUnknown
-
PharmaxisCompleted
-
PharmaxisCompletedCystic FibrosisUnited Kingdom
-
University of British ColumbiaCompleted
-
PharmaxisWithdrawnCOPD | ExacerbationAustralia
-
Kuopio University HospitalJohn Hunter HospitalRecruiting
-
Abela Pharmaceuticals, Inc.Ohio State University; University of California, Irvine; Dr. Mahajan's Hospital...UnknownSevere Head TraumaUnited States